Pharmaceutical

GS-4528 by Gilead Sciences for Metastatic Renal Cell Carcinoma: Likelihood of Approval

GS-4528 is under clinical development by Gilead Sciences and currently in Phase I for Metastatic Renal Cell Carcinoma.

Dec 26, 2023 - 18:00
GS-4528 is under clinical development by Gilead Sciences and currently in Phase I for Metastatic Renal Cell Carcinoma.
Read the original article

Tags:

Previous Article

NT-175 by Neogene Therapeutics for Head And Neck Squamous Cell Carcinoma (HNSC):...

Next Article

ADRX-0706 by Adcentrx Therapeutics for Head And Neck Squamous Cell Carcinoma (HN...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

How regenerative medicine M&A performed in the pharmace...

Jul 31, 2023

BioNTech partners with Autolus to advance CAR-T therapies

BioNTech partners with Autolus to advance CAR-T therapies

Feb 10, 2024

STAT+: Medicare is urged to consider Amgen patent maneuvers when negotiating the price for a drug

STAT+: Medicare is urged to consider Amgen patent maneu...

Nov 1, 2023